Yiming Cheng1, Liangang Liu2, Yongjun Xue3, Simon Zhou1, Yan Li4. 1. Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, 556 Morris Ave, Summit, NJ, 07901, USA. 2. Global Biometrics and Data Sciences, Bristol Myers Squibb, Berkeley Heights, NJ, USA. 3. Non-Clinical Research and Development, Bristol Myers Squibb, Princeton, NJ, USA. 4. Clinical Pharmacology and Pharmacometrics, Bristol Myers Squibb, 556 Morris Ave, Summit, NJ, 07901, USA. yan.li@bms.com.
Abstract
BACKGROUND AND OBJECTIVE: CC-292 is a potent, selective, orally administered small molecule inhibitor of Bruton's tyrosine kinase (BTK). To support the clinical investigation of CC-292, a randomized, seven-treatment, seven-period, crossover study was conducted to assess the relative bioavailability, pH effect, food effect, and dose-proportionality of two formulated tablets of CC-292. METHODS: Healthy subjects (n = 24) were enrolled in the study and randomly assigned into different treatment sequences. Blood samples were collected at pre-specified time points to measure the drug concentrations in plasma. Statistical analyses were performed to compare the pharmacokinetics of CC-292 under different conditions. RESULTS: The relative bioavailability of the newly developed formulation [spray-dried dispersion (SDD)] to the reference formulation (P22) was 1.24. When a single dose of CC-292 SDD tablet was administered under fed conditions, the area under the plasma concentration-time curve from time zero to infinity (AUC∞) increased by 10.9% and the maximum plasma drug concentration Cmax) decreased by 19.4% compared to when CC-292 was administered under fasted conditions. When a single dose of CC-292 SDD tablet was administered after multiple doses of omeprazole, the area under the plasma concentration-time curve from time zero to infinity (AUC∞) decreased by 36.8% and the maximum plasma drug concentration Cmax) decreased by 48.1% compared to when CC-292 was administered alone. Over a dose range of 100-300 mg (SDD formulation), CC-292 exhibited more than dose-proportional increases of drug exposures. CONCLUSIONS: CC-292 was well tolerated when administered to healthy subjects as single oral doses under all conditions. Food intake had no clinically relevant impact on CC-292 pharmacokinetics compared to fasted conditions. Therefore, CC-292 can be administered with or without food. Co-administration of CC-292 with multiple doses of omeprazole (40 mg) decreased the pharmacokinetic exposure of CC-292. However, the effect was not clinically relevant. CLINICAL TRIALS REGISTRATION: NCT02433457.
BACKGROUND AND OBJECTIVE: CC-292 is a potent, selective, orally administered small molecule inhibitor of Bruton's tyrosine kinase (BTK). To support the clinical investigation of CC-292, a randomized, seven-treatment, seven-period, crossover study was conducted to assess the relative bioavailability, pH effect, food effect, and dose-proportionality of two formulated tablets of CC-292. METHODS: Healthy subjects (n = 24) were enrolled in the study and randomly assigned into different treatment sequences. Blood samples were collected at pre-specified time points to measure the drug concentrations in plasma. Statistical analyses were performed to compare the pharmacokinetics of CC-292 under different conditions. RESULTS: The relative bioavailability of the newly developed formulation [spray-dried dispersion (SDD)] to the reference formulation (P22) was 1.24. When a single dose of CC-292 SDD tablet was administered under fed conditions, the area under the plasma concentration-time curve from time zero to infinity (AUC∞) increased by 10.9% and the maximum plasma drug concentration Cmax) decreased by 19.4% compared to when CC-292 was administered under fasted conditions. When a single dose of CC-292 SDD tablet was administered after multiple doses of omeprazole, the area under the plasma concentration-time curve from time zero to infinity (AUC∞) decreased by 36.8% and the maximum plasma drug concentration Cmax) decreased by 48.1% compared to when CC-292 was administered alone. Over a dose range of 100-300 mg (SDD formulation), CC-292 exhibited more than dose-proportional increases of drug exposures. CONCLUSIONS: CC-292 was well tolerated when administered to healthy subjects as single oral doses under all conditions. Food intake had no clinically relevant impact on CC-292 pharmacokinetics compared to fasted conditions. Therefore, CC-292 can be administered with or without food. Co-administration of CC-292 with multiple doses of omeprazole (40 mg) decreased the pharmacokinetic exposure of CC-292. However, the effect was not clinically relevant. CLINICAL TRIALS REGISTRATION: NCT02433457.
Authors: Jennifer R Brown; Wael A Harb; Brian T Hill; Janice Gabrilove; Jeff P Sharman; Marshall T Schreeder; Paul M Barr; James M Foran; Thomas P Miller; Jan A Burger; Kevin R Kelly; Daruka Mahadevan; Shuo Ma; Yan Li; Daniel W Pierce; Evelyn Barnett; Jeffrey Marine; Monika Miranda; Ada Azaryan; Xujie Yu; Pilar Nava-Parada; Jay Mei; Thomas J Kipps Journal: Haematologica Date: 2016-05-05 Impact factor: 9.941
Authors: Abdalla J Mohamed; Liang Yu; Carl-Magnus Bäckesjö; Leonardo Vargas; Rani Faryal; Alar Aints; Birger Christensson; Anna Berglöf; Mauno Vihinen; Beston F Nore; C I Edvard Smith Journal: Immunol Rev Date: 2009-03 Impact factor: 12.988
Authors: Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith Journal: N Engl J Med Date: 2008-02-14 Impact factor: 91.245
Authors: Erica K Evans; Richland Tester; Sharon Aslanian; Russell Karp; Michael Sheets; Matthew T Labenski; Steven R Witowski; Heather Lounsbury; Prasoon Chaturvedi; Hormoz Mazdiyasni; Zhendong Zhu; Mariana Nacht; Martin I Freed; Russell C Petter; Alex Dubrovskiy; Juswinder Singh; William F Westlin Journal: J Pharmacol Exp Ther Date: 2013-05-24 Impact factor: 4.030
Authors: C I Smith; B Baskin; P Humire-Greiff; J N Zhou; P G Olsson; H S Maniar; P Kjellén; J D Lambris; B Christensson; L Hammarström Journal: J Immunol Date: 1994-01-15 Impact factor: 5.422
Authors: Yan Li; Francisco Ramírez-Valle; Yongjun Xue; Judith I Ventura; Olivier Gouedard; Jay Mei; Kenichi Takeshita; Maria Palmisano; Simon Zhou Journal: J Clin Pharmacol Date: 2017-05-19 Impact factor: 3.126
Authors: Peter H Schafer; Alan J Kivitz; Jianglin Ma; Shimon Korish; Donna Sutherland; Li Li; Ada Azaryan; Jolanta Kosek; Mary Adams; Lori Capone; Eun Mi Hur; Douglas R Hough; Garth E Ringheim Journal: Rheumatol Ther Date: 2019-11-13